Translating bariatric surgery weight loss into a pill

As pharmas and biotechs alike crowd into the GLP-1 space in obesity, Kallyope thinks its approach of replicating — and magnifying — a weight loss mechanism induced by bariatric surgery could differentiate its oral therapy from the pack.

The commercial success of Wegovy semaglutide and Zepbound tirzepatide from obesity leaders Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY) has led other pharmas to enter the field and brought dozens of biotechs with obesity programs out of the woodwork. Yet most of the clinical pipeline remains focused on GLP-1 agonists either as monotherapy or the backbone of a combination strategy. ...